Double-blind, randomized, placebo-controlled, parallel-group, two-arm, multi-center phase II trial to assess the safety, tolerability, and efficacy of DP-VPA (up to 900 mg) once daily for 10 weeks in adult subjects with migraine
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 06 May 2009
At a glance
- Drugs DP-VPA (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors D-Pharm
- 06 May 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 12 Apr 2008 New trial record.